期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 59, 期 10, 页码 6605-6607出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01165-15
关键词
-
Ceftazidime-avibactam is the first antimicrobial approved by the U.S. FDA for the treatment of carbapenem-resistant Enterobacteriaceae. Avibactam, a non-beta-lactam beta-lactamase inhibitor, inactivates class A serine carbapenemases, including Klebsiella pneumoniae carbapenemase (KPC). We report a KPC-producing K. pneumoniae isolate resistant to ceftazidime-avibactam (MIC, 32/4 mu g/ml) from a patient with no prior treatment with ceftazidime-avibactam.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据